Soluble ST2 in Patients With Heart Failure"
" Prognostic Value of Soluble ST2 Beyond B-Type Natriuretic Peptide in Management of Patients With Heart Failure"
1 other identifier
observational
100
0 countries
N/A
Brief Summary
- 1.The aim of this study was to explore the relationship between peripheral circulating serum soluble suppression of tumorigenicity-2 (sST2) levels and inflammatory biomarkers in patients with heart failure
- 2.Additive role of sST2 to NPs in of heart failure patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2024
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2024
CompletedFirst Posted
Study publicly available on registry
May 23, 2024
CompletedStudy Start
First participant enrolled
July 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2027
May 23, 2024
May 1, 2024
2 years
May 12, 2024
May 17, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
To evaluate if Soluble ST2 is strongly associated with measures of HF severity and poor outcome
Study ST2 level in heart failure patients and correlate results with clinical data and other inflammatory biomarker
Baseline
Evaluation of BNP and ST2 could have a potential role in prognosis.
Study value of BNP in prognosis and compare it with ST2
Baseline
Secondary Outcomes (1)
• Clinical Impact and Treatment Decision Support
Baseline
Study Arms (3)
Group I
HF with reduced ejection fraction (HFrEF, LVEF ≤ 40%)
Group II
HF with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%)
Group III
HF with preserved ejection fraction (HFpEF, LVEF ≥ 50%)
Interventions
ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
Eligibility Criteria
The study will be conducted at Chemistry unit of Clinical Pathology Department and Cardiovascular Department, Assiut University Hospitals, Assiut University, Egypt Heart failure patients will be classified according to NYHA classification
You may qualify if:
- patients 18-80 years.
- Both sexes will be included.
- including signs and symptoms of HF (e.g., elevated jugular venous pressure and altered apical beat position), altered LVEF (\< 40%; 40%-49%; ≥ 50%)
You may not qualify if:
- Patients \<18 years
- Patients with documented evidence of cardiogenic shock .
- Patients with Acute coronary syndrome within 30 days.
- chronic kidney disease patients with glomerular filtration rate \< 30
- Patients with interstitial pulmonary fibrosis .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Purdy GE, Payne SM. The SHI-3 iron transport island of Shigella boydii 0-1392 carries the genes for aerobactin synthesis and transport. J Bacteriol. 2001 Jul;183(14):4176-82. doi: 10.1128/JB.183.14.4176-4182.2001.
PMID: 11418557BACKGROUND
Study Officials
- STUDY DIRECTOR
Randa Ahmed
Assiut University
- STUDY DIRECTOR
Hanan Omer
Assiut University
- STUDY DIRECTOR
Yousra Mamdouh
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- doctor
Study Record Dates
First Submitted
May 12, 2024
First Posted
May 23, 2024
Study Start
July 1, 2024
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
January 1, 2027
Last Updated
May 23, 2024
Record last verified: 2024-05